Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for NRIX

Stock Name	Nurix Therapeutics Inc
Ticker	NRIX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US67080M1036

Show aggregate NRIX holdings

News associated with NRIX

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $28.87 Consensus Target Price from Brokerages: Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the sixteen research firms that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price target […] - 2025-08-27 02:54:56
18,716 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Purchased by XTX Topco Ltd: XTX Topco Ltd purchased a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 18,716 shares of the company’s stock, valued at approximately $222,000. Other institutional investors and hedge funds have also […] - 2025-08-13 04:26:46
TD Asset Management Inc Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX): TD Asset Management Inc increased its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,420 shares of the company’s stock after purchasing an additional 3,186 […] - 2025-08-05 04:34:52
HC Wainwright Lowers Nurix Therapeutics (NASDAQ:NRIX) Price Target to $34.00: Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its target price cut by equities research analysts at HC Wainwright from $36.00 to $34.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 179.84% from the stock’s previous […] - 2025-07-16 04:26:52
Analysts Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $30.18: Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have received an average recommendation of “Moderate Buy” from the eighteen ratings firms that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 12 month […] - 2025-07-08 03:10:44
Nurix: European Medicines Agency Grants Orphan Drug Designation To Bexobrutideg: (RTTNews) - Nurix Therapeutics (NRIX) announced that the European Medicines Agency has granted Orphan Drug Designation to bexobrutideg for the treatment of lymphoplasmacytic lymphoma. Bexobrutideg is an orally bioavailable, brain penetrant degrader of Brutons tyrosine kinase whic - 2025-07-07 08:41:27
Sumitomo Mitsui Trust Group Inc. Sells 33,252 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX): Sumitomo Mitsui Trust Group Inc. reduced its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 4.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 755,970 shares of the company’s stock after selling 33,252 shares during the […] - 2025-07-04 05:13:03
Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Price Target at $30.18: Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eighteen research firms that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average 12-month target price […] - 2025-06-13 02:32:51
The Math Shows ESML Can Go To $48: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-05 07:20:56
ProShare Advisors LLC Acquires 7,261 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX): ProShare Advisors LLC lifted its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 45.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,132 shares of the company’s stock after buying an additional 7,261 shares during the period. […] - 2025-05-28 05:09:01
Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Price Target at $30.44: Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nineteen ratings firms that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average 1-year price […] - 2025-05-19 02:32:50
First Trust Advisors LP Acquires New Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX): First Trust Advisors LP bought a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 135,903 shares of the company’s stock, valued at approximately $2,560,000. First Trust Advisors LP owned approximately […] - 2025-05-05 06:24:57
Invesco Ltd. Sells 361,360 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX): Invesco Ltd. lessened its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 87.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,980 shares of the company’s stock after selling 361,360 shares during the quarter. Invesco Ltd.’s holdings […] - 2025-05-02 05:06:53
Norges Bank Purchases Shares of 318,800 Nurix Therapeutics, Inc. (NASDAQ:NRIX): Norges Bank acquired a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm acquired 318,800 shares of the company’s stock, valued at approximately $6,006,000. Other institutional investors also recently bought and sold shares of the company. NEOS Investment Management LLC purchased a new stake in […] - 2025-04-10 05:34:49
Vanguard Group Inc. Has $81.87 Million Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX): Vanguard Group Inc. boosted its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.3% during the 4th quarter, HoldingsChannel reports. The fund owned 4,345,266 shares of the company’s stock after acquiring an additional 333,452 shares during the quarter. Vanguard Group Inc. owned about 0.06% of Nurix Therapeutics worth $81,865,000 as of its most […] - 2025-04-10 04:44:59
Peek Under The Hood: DFAC Has 28% Upside: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-04 08:47:40
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Recommendation of “Moderate Buy” by Brokerages: Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have received a consensus rating of “Moderate Buy” from the eighteen analysts that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 12-month price […] - 2025-03-27 04:38:49
US Bancorp DE Has $27,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX): US Bancorp DE raised its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 144.7% in the 4th quarter, HoldingsChannel reports. The fund owned 1,424 shares of the company’s stock after acquiring an additional 842 shares during the period. US Bancorp DE’s holdings in Nurix Therapeutics were worth $27,000 at the end of the […] - 2025-03-20 06:28:53
Bank of New York Mellon Corp Purchases 15,639 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX): Bank of New York Mellon Corp lifted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 190,905 shares of the company’s stock after buying an additional 15,639 shares during the […] - 2025-03-20 06:28:53
Leerink Partners Initiates Coverage on Nurix Therapeutics (NASDAQ:NRIX): Leerink Partners began coverage on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a report published on Monday morning, MarketBeat Ratings reports. The firm issued a market perform rating and a $16.00 price target on the stock. Several other equities analysts also recently commented on the company. HC Wainwright increased their price target on […] - 2025-03-18 04:30:53
Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $31.81: Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 1-year price objective […] - 2025-03-05 04:53:07
Rhumbline Advisers Acquires 12,315 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX): Rhumbline Advisers raised its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 13.5% during the fourth quarter, Holdings Channel reports. The firm owned 103,233 shares of the company’s stock after buying an additional 12,315 shares during the quarter. Rhumbline Advisers’ holdings in Nurix Therapeutics were worth $1,945,000 at the end of […] - 2025-03-04 06:10:55
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Expected to Rise, Morgan Stanley Analyst Says: Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its price objective lifted by analysts at Morgan Stanley from $16.00 to $17.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price target indicates a potential downside of 8.55% from […] - 2025-02-05 04:44:53

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) NRIX holdings

Date	Number of NRIX Shares Held	Base Market Value of NRIX Shares	Local Market Value of NRIX Shares	Change in NRIX Shares Held	Change in NRIX Base Value	Current Price per NRIX Share Held	Previous Price per NRIX Share Held
2025-11-12 (Wednesday)	51,761	USD 629,931	USD 629,931	133	USD -34,005	USD 12.17	USD 12.86
2025-11-11 (Tuesday)	51,628	USD 663,936	USD 663,936	0	USD 31,493	USD 12.86	USD 12.25
2025-11-10 (Monday)	51,628	USD 632,443	USD 632,443	133	USD -1,460	USD 12.25	USD 12.31
2025-11-07 (Friday)	51,495	USD 633,903	USD 633,903	0	USD -10,814	USD 12.31	USD 12.52
2025-11-06 (Thursday)	51,495	USD 644,717	USD 644,717	133	USD 5,003	USD 12.52	USD 12.455
2025-11-05 (Wednesday)	51,362	USD 639,714	USD 639,714	0	USD 10,016	USD 12.455	USD 12.26
2025-11-04 (Tuesday)	51,362	USD 629,698	USD 629,698	134	USD -16,799	USD 12.26	USD 12.62
2025-11-03 (Monday)	51,228	USD 646,497	USD 646,497	0	USD -16,393	USD 12.62	USD 12.94
2025-10-31 (Friday)	51,228	USD 662,890	USD 662,890	0	USD 8,196	USD 12.94	USD 12.78
2025-10-30 (Thursday)	51,228	USD 654,694	USD 654,694	670	USD 63,165	USD 12.78	USD 11.7
2025-10-29 (Wednesday)	50,558	USD 591,529	USD 591,529	268	USD -6,922	USD 11.7	USD 11.9
2025-10-28 (Tuesday)	50,290	USD 598,451	USD 598,451	0	USD -4,023	USD 11.9	USD 11.98
2025-10-27 (Monday)	50,290	USD 602,474	USD 602,474	0	USD 44,758	USD 11.98	USD 11.09

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NRIX by Blackrock for IE00BDZVHG35

Show aggregate share trades of NRIX

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-12 BUY 133 13.150 12.150 12.250 USD 1,629 14.54
2025-11-10 BUY 133 12.800 12.200 12.260 USD 1,631 14.56
2025-11-06 BUY 133 12.880 12.300 12.358 USD 1,644 14.59
2025-11-04 BUY 134 12.530 12.160 12.197 USD 1,634 14.61
2025-10-30 BUY 670 13.235 11.575 11.741 USD 7,866 14.64
2025-10-29 BUY 268 11.700 12.010 11.979 USD 3,210 14.66
2025-10-22 SELL -532 10.630 11.700 11.593 USD -6,167 14.76 Profit of 1,683 on sale
2025-10-20 BUY 266 10.390 10.470 10.462 USD 2,783 14.81
2025-10-17 BUY 664 9.840 10.174 10.141 USD 6,733 14.84
2025-10-15 BUY 1,056 10.350 10.430 10.422 USD 11,006 14.86
2025-10-03 BUY 938 9.380 9.490 9.479 USD 8,891 14.93
2025-10-02 BUY 134 9.080 9.690 9.629 USD 1,290 14.97
2025-09-30 BUY 268 9.240 9.410 9.393 USD 2,517 15.03
2025-09-26 BUY 270 8.930 9.066 9.052 USD 2,444 15.11
2025-09-25 BUY 270 8.330 8.689 8.653 USD 2,336 15.15
2025-09-18 BUY 136 8.970 9.060 9.051 USD 1,231 15.19
2025-09-17 BUY 408 8.570 9.060 9.011 USD 3,676 15.23
2025-07-17 SELL -266 12.090 12.560 12.513 USD -3,328 15.35 Profit of 753 on sale
2025-07-11 SELL -1,064 12.440 12.900 12.854 USD -13,677 15.42 Profit of 2,733 on sale
2025-07-02 BUY 7,315 12.440 12.900 12.854 USD 94,027 15.50
2025-06-25 BUY 266 11.620 11.985 11.948 USD 3,178 15.60
2025-06-20 BUY 2,324 11.490 11.880 11.841 USD 27,518 15.68
2025-06-11 BUY 252 12.630 13.090 13.044 USD 3,287 15.89
2025-06-10 BUY 252 12.790 13.035 13.010 USD 3,279 15.91
2025-06-04 SELL -126 12.160 12.390 12.367 USD -1,558 16.02 Profit of 460 on sale
2025-04-23 BUY 126 11.610 12.380 12.303 USD 1,550 17.72
2025-04-10 SELL -1,008 8.810 9.930 9.818 USD -9,897 18.50 Profit of 8,756 on sale
2025-04-08 SELL -126 9.260 10.390 10.277 USD -1,295 18.71 Profit of 1,063 on sale
2025-04-07 SELL -126 9.720 9.910 9.891 USD -1,246 18.82 Profit of 1,125 on sale
2025-04-04 SELL -630 9.690 10.520 10.437 USD -6,575 18.93 Profit of 5,347 on sale
2025-04-01 BUY 520 10.470 11.890 11.748 USD 6,109 19.12
2025-03-31 SELL -378 11.880 12.030 12.015 USD -4,542 19.21 Profit of 2,718 on sale
2025-03-21 BUY 4,106 12.990 13.670 13.602 USD 55,850 19.72
2025-03-14 SELL -1,808 13.590 13.640 13.635 USD -24,652 20.14 Profit of 11,753 on sale
2025-03-07 SELL -226 13.860 14.290 14.247 USD -3,220 20.61 Profit of 1,439 on sale
2025-03-04 SELL -113 14.260 14.580 14.548 USD -1,644 20.92 Profit of 720 on sale
2025-02-25 BUY 226 16.470 16.980 16.929 USD 3,826 21.38
2025-02-19 SELL -112 17.350 17.405 17.400 USD -1,949 21.70 Profit of 481 on sale
2025-02-13 BUY 336 17.570 17.850 17.822 USD 5,988 22.04
2025-02-12 BUY 112 17.310 17.350 17.346 USD 1,943 22.14
2025-02-11 BUY 448 17.120 18.180 18.074 USD 8,097 22.24
2024-12-30 SELL -565 18.640 19.085 19.040 USD -10,758 23.58 Profit of 2,567 on sale
2024-11-18 SELL -1,665 21.790 22.710 22.618 USD -37,659 25.70 Profit of 5,123 on sale
2024-11-08 SELL -111 27.340 27.750 27.709 USD -3,076 25.48 Loss of -247 on sale
2024-10-21 SELL -111 25.480 25.880 25.840 USD -2,868 0.00 Loss of -2,868 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-12	BUY	133	13.150	12.150	12.250	USD 1,629	14.54
2025-11-10	BUY	133	12.800	12.200	12.260	USD 1,631	14.56
2025-11-06	BUY	133	12.880	12.300	12.358	USD 1,644	14.59
2025-11-04	BUY	134	12.530	12.160	12.197	USD 1,634	14.61
2025-10-30	BUY	670	13.235	11.575	11.741	USD 7,866	14.64
2025-10-29	BUY	268	11.700	12.010	11.979	USD 3,210	14.66
2025-10-22	SELL	-532	10.630	11.700	11.593	USD -6,167	14.76 Profit of 1,683 on sale
2025-10-20	BUY	266	10.390	10.470	10.462	USD 2,783	14.81
2025-10-17	BUY	664	9.840	10.174	10.141	USD 6,733	14.84
2025-10-15	BUY	1,056	10.350	10.430	10.422	USD 11,006	14.86
2025-10-03	BUY	938	9.380	9.490	9.479	USD 8,891	14.93
2025-10-02	BUY	134	9.080	9.690	9.629	USD 1,290	14.97
2025-09-30	BUY	268	9.240	9.410	9.393	USD 2,517	15.03
2025-09-26	BUY	270	8.930	9.066	9.052	USD 2,444	15.11
2025-09-25	BUY	270	8.330	8.689	8.653	USD 2,336	15.15
2025-09-18	BUY	136	8.970	9.060	9.051	USD 1,231	15.19
2025-09-17	BUY	408	8.570	9.060	9.011	USD 3,676	15.23
2025-07-17	SELL	-266	12.090	12.560	12.513	USD -3,328	15.35 Profit of 753 on sale
2025-07-11	SELL	-1,064	12.440	12.900	12.854	USD -13,677	15.42 Profit of 2,733 on sale
2025-07-02	BUY	7,315	12.440	12.900	12.854	USD 94,027	15.50
2025-06-25	BUY	266	11.620	11.985	11.948	USD 3,178	15.60
2025-06-20	BUY	2,324	11.490	11.880	11.841	USD 27,518	15.68
2025-06-11	BUY	252	12.630	13.090	13.044	USD 3,287	15.89
2025-06-10	BUY	252	12.790	13.035	13.010	USD 3,279	15.91
2025-06-04	SELL	-126	12.160	12.390	12.367	USD -1,558	16.02 Profit of 460 on sale
2025-04-23	BUY	126	11.610	12.380	12.303	USD 1,550	17.72
2025-04-10	SELL	-1,008	8.810	9.930	9.818	USD -9,897	18.50 Profit of 8,756 on sale
2025-04-08	SELL	-126	9.260	10.390	10.277	USD -1,295	18.71 Profit of 1,063 on sale
2025-04-07	SELL	-126	9.720	9.910	9.891	USD -1,246	18.82 Profit of 1,125 on sale
2025-04-04	SELL	-630	9.690	10.520	10.437	USD -6,575	18.93 Profit of 5,347 on sale
2025-04-01	BUY	520	10.470	11.890	11.748	USD 6,109	19.12
2025-03-31	SELL	-378	11.880	12.030	12.015	USD -4,542	19.21 Profit of 2,718 on sale
2025-03-21	BUY	4,106	12.990	13.670	13.602	USD 55,850	19.72
2025-03-14	SELL	-1,808	13.590	13.640	13.635	USD -24,652	20.14 Profit of 11,753 on sale
2025-03-07	SELL	-226	13.860	14.290	14.247	USD -3,220	20.61 Profit of 1,439 on sale
2025-03-04	SELL	-113	14.260	14.580	14.548	USD -1,644	20.92 Profit of 720 on sale
2025-02-25	BUY	226	16.470	16.980	16.929	USD 3,826	21.38
2025-02-19	SELL	-112	17.350	17.405	17.400	USD -1,949	21.70 Profit of 481 on sale
2025-02-13	BUY	336	17.570	17.850	17.822	USD 5,988	22.04
2025-02-12	BUY	112	17.310	17.350	17.346	USD 1,943	22.14
2025-02-11	BUY	448	17.120	18.180	18.074	USD 8,097	22.24
2024-12-30	SELL	-565	18.640	19.085	19.040	USD -10,758	23.58 Profit of 2,567 on sale
2024-11-18	SELL	-1,665	21.790	22.710	22.618	USD -37,659	25.70 Profit of 5,123 on sale
2024-11-08	SELL	-111	27.340	27.750	27.709	USD -3,076	25.48 Loss of -247 on sale
2024-10-21	SELL	-111	25.480	25.880	25.840	USD -2,868	0.00 Loss of -2,868 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NRIX

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	76,869	0	337,089	22.8%
2025-09-18	115,926	97	470,434	24.6%
2025-09-17	126,671	0	672,961	18.8%
2025-09-16	103,850	0	416,879	24.9%
2025-09-15	262,191	0	512,074	51.2%
2025-09-12	144,962	0	456,366	31.8%
2025-09-11	113,184	0	213,493	53.0%
2025-09-10	110,091	853	183,502	60.0%
2025-09-09	136,763	0	288,470	47.4%
2025-09-08	123,946	5	228,588	54.2%
2025-09-05	123,937	0	238,538	52.0%
2025-09-04	72,940	0	129,918	56.1%
2025-09-03	181,068	0	299,306	60.5%
2025-09-02	76,510	0	353,687	21.6%
2025-08-29	203,278	42	356,573	57.0%
2025-08-28	55,246	0	151,084	36.6%
2025-08-27	71,617	3,905	118,660	60.4%
2025-08-26	86,489	20	165,947	52.1%
2025-08-25	41,394	0	100,220	41.3%
2025-08-22	65,645	0	165,093	39.8%
2025-08-21	58,041	166	177,377	32.7%
2025-08-20	67,997	0	191,754	35.5%
2025-08-19	97,083	865	296,240	32.8%
2025-08-18	80,471	0	1,066,527	7.5%
2025-08-15	59,912	0	124,040	48.3%
2025-08-14	79,225	0	116,844	67.8%
2025-08-13	97,433	0	177,943	54.8%
2025-08-12	73,474	77	151,976	48.3%
2025-08-11	103,917	53	233,589	44.5%
2025-08-08	85,699	0	162,586	52.7%
2025-08-07	70,588	0	116,889	60.4%
2025-08-06	215,458	41	268,136	80.4%
2025-08-05	78,095	0	149,090	52.4%
2025-08-04	70,141	4	117,121	59.9%
2025-08-01	99,674	85	116,924	85.2%
2025-07-31	218,945	0	624,755	35.0%
2025-07-30	162,585	4,925	194,367	83.6%
2025-07-29	180,029	442	376,034	47.9%
2025-07-28	251,755	0	464,585	54.2%
2025-07-25	78,115	26	128,306	60.9%
2025-07-24	89,575	429	240,857	37.2%
2025-07-23	79,373	0	288,378	27.5%
2025-07-22	102,193	0	188,093	54.3%
2025-07-21	81,204	0	127,391	63.7%
2025-07-18	156,582	1,615	261,963	59.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE